Ras signaling in leukemogenesis
白血病发生中的 Ras 信号传导
基本信息
- 批准号:7778902
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-01 至 2012-02-28
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAllelesBiochemicalBiologicalBiological AssayBone MarrowCell CommunicationCell ProliferationCell membraneCellsChronic Myelomonocytic LeukemiaComplexCultured CellsDevelopmentDiseaseEnvironmentEnzymesEventGenesGoalsHematologic NeoplasmsHematopoieticKnock-outKnockout MiceLaboratory StudyMediatingMembraneMethylationModelingModificationMolecularMusMutationMyeloproliferative diseaseOncogene ProteinsOncogenicOutputPlayPost-Translational Protein ProcessingProcessRelative (related person)ReportingRestRoleSignal TransductionSiteSolid NeoplasmTestingTherapeutic InterventionTransplantationcancer therapycell typefarnesylationimprovedin vivoleukemialeukemogenesismetaplastic cell transformationmouse modelmutantpalmitoylationprotein-S-isoprenylcysteine O-methyltransferaseras Proteinstumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Ras proteins are crucial regulators of cell proliferation, survival and differentiation. Aberrant activation of Ras proteins, either by Ras mutations or by altering genes that directly or indirectly regulate Ras, is common in both solid tumors and hematologic malignancies. Ras proteins can interact with a wide spectrum of Ras effectors that play either positive or negative roles in the control of cell proliferation and survival. The association with different microdomains of the plasma membrane as well as other internal cell membranes may allow different Ras proteins to access to different pools of Ras effectors and to generate distinct signal outputs. In the past, laboratory studies of the roles of Ras effectors in oncogenesis have been performed mostly in cultured cells. And even in these assays, cellular transformation of different cell types was shown to require different Ras effectors. Leukemogenesis is a complex process that not only involves the effects of oncogenic mutation(s) within the target cells, but interactions of such cells with the rest of the in vivo environment. The overall hypothesis of this proposal is that the in vivo leukemogenesis by oncogenic Ras may involve unique Ras signaling networks. We have previously examined the leukemogenicity of oncogenic N-Ras using an improved mouse bone marrow transduction and transplantation model and found that oncogenic N-Ras efficiently induced myeloproliferative disorder and acute myelogenous leukemia-like disease in mice. We will use this mouse model to test the hypothesis stated above by examining the roles of various post-translational modifications and effectors of Ras in N-Ras leukemogenesis. The specific aims for this proposal are: 1. To determine the roles of post-translational modifications of N-Ras in leukemogenesis by a mutational analysis of the modification sites of oncogenic N-Ras, as well as by analyzing N-Ras leukemogenesis in mice with conditional knockout alleles of Reel or Icmt (genes encoding the Ras converting enzyme and isoprenylcysteine carboxyl methyltransferase, respectively). 2. To determine the roles of downstream effectors of Ras in N-Ras leukemogenesis by a combination of biological and biochemical approaches, using effector domain mutants of the oncogenic N-Ras, as well as activated and inhibitory forms of various effectors of Ras. The ultimate goal of these studies is to identify critical molecular events in Ras leukemogenesis, allowing therapeutic interventions of leukemias involving Ras.
描述(由申请人提供):RAS蛋白是细胞增殖,生存和分化的关键调节剂。通过RAS突变或通过直接或间接调节Ras的基因的异常激活在实体瘤和血液学恶性肿瘤中都是常见的。 RAS蛋白可以与广泛的RAS效应子相互作用,这些RAS效应子在控制细胞增殖和存活中起着阳性或负作用。与质膜以及其他内部细胞膜的不同微区域的关联可能使不同的RAS蛋白可以访问不同的RAS效应子池并产生不同的信号输出。过去,关于RAS效应子在肿瘤发生中作用的实验室研究主要是在培养的细胞中进行的。即使在这些测定中,不同细胞类型的细胞转化也被证明需要不同的RAS效应子。白血病是一个复杂的过程,不仅涉及靶细胞内致癌突变的作用,而且还涉及此类细胞与其余体内环境的相互作用。该提议的总体假设是,致癌性RAS的体内白血病发生可能涉及独特的RAS信号网络。我们先前使用改进的小鼠骨髓转导和移植模型检查了致癌N-RAS的白血病性,并发现致癌N-RAS在小鼠中有效诱导了脊髓增生性疾病和急性脊髓脊髓性白血病样疾病。我们将使用该小鼠模型来检验上述假设,通过研究RAS在N-RAS白血病发生中的各种翻译后修饰和效应子的作用。该提案的具体目的是:1。通过对致癌N-RAS的修饰位点的突变分析以及通过分析小鼠N-RAS白细胞发育作用,以确定N-RAS在白血病发生中的翻译后修饰的作用。使用卷轴或ICMT的条件基因敲除等位基因(编码RAS转化酶和异位肾上腺半胱氨酸羧基甲基转移酶的基因)。 2。通过结合生物学和生物化学方法的结合,使用了致癌n-Ras的效应域突变体,以及RAS的各种效应子的激活和抑制形式。这些研究的最终目的是确定RAS白血病发生中的关键分子事件,从而使涉及RA的白血病的治疗干预措施。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ruibao Ren其他文献
Ruibao Ren的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ruibao Ren', 18)}}的其他基金
IDENTIFICATION OF TARGETS OF BCR ABL IN THE LEUKEMOGENIC
白血病中 BCR ABL 靶点的识别
- 批准号:
6286186 - 财政年份:1996
- 资助金额:
$ 34.65万 - 项目类别:
BCR-ABL TARGET IDENTIFICATION IN THE LEUKEMOGENIC
白血病中的 BCR-ABL 靶标识别
- 批准号:
2376975 - 财政年份:1996
- 资助金额:
$ 34.65万 - 项目类别:
IDENTIFICATION OF TARGETS OF BCR ABL IN THE LEUKEMOGENIC
白血病中 BCR ABL 靶点的识别
- 批准号:
6512760 - 财政年份:1996
- 资助金额:
$ 34.65万 - 项目类别:
BCR-ABL TARGET IDENTIFICATION IN THE LEUKEMOGENIC
白血病中的 BCR-ABL 靶标识别
- 批准号:
2668016 - 财政年份:1996
- 资助金额:
$ 34.65万 - 项目类别:
BCR-ABL TARGET IDENTIFICATION IN THE LEUKEMOGENIC PATHWA
白血病途径中的 BCR-ABL 靶标识别
- 批准号:
6164192 - 财政年份:1996
- 资助金额:
$ 34.65万 - 项目类别:
IDENTIFICATION OF TARGETS OF BCR ABL IN THE LEUKEMOGENIC
白血病中 BCR ABL 靶点的识别
- 批准号:
6704198 - 财政年份:1996
- 资助金额:
$ 34.65万 - 项目类别:
相似国自然基金
等位基因聚合网络模型的构建及其在叶片茸毛发育中的应用
- 批准号:32370714
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
- 批准号:82300353
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠杆菌多粘菌素异质性耐药中phoPQ等位基因差异介导不同亚群共存的机制研究
- 批准号:82302575
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACR11A不同等位基因调控番茄低温胁迫的机理解析
- 批准号:32302535
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
玉米穗行数QTL克隆及优异等位基因型鉴定
- 批准号:
- 批准年份:2022
- 资助金额:55 万元
- 项目类别:面上项目
相似海外基金
Development of high-throughput cellular models for ASXL1-related diseases
ASXL1相关疾病高通量细胞模型的开发
- 批准号:
10727983 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma
针对分子定义的难治性黑色素瘤子集的新型细胞治疗方法
- 批准号:
10780289 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Mutant p53 in pathogenesis of Myelodysplastic Syndromes
突变型 p53 在骨髓增生异常综合征发病机制中的作用
- 批准号:
10313142 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Mutant p53 in pathogenesis of Myelodysplastic Syndromes
突变型 p53 在骨髓增生异常综合征发病机制中的作用
- 批准号:
10592239 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Splicing Modulators for Rare Disease Indications
用于罕见疾病适应症的剪接调节剂
- 批准号:
10501840 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别: